Monteverde & Associates Investigates Cyclerion Therapeutics Merger

The M&A class action firm is looking into the fairness of Cyclerion's proposed acquisition by Korsana Biosciences.

Apr. 2, 2026 at 7:10pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a pair of reading glasses, conceptually representing the abstract legal proceedings surrounding a corporate merger.A class action law firm investigates the fairness of a major corporate merger, signaling potential concerns for shareholders.NYC Today

Monteverde & Associates PC, a national class action securities firm, has announced an investigation into the proposed merger between Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. The firm is examining whether the terms of the deal are fair to Cyclerion shareholders, who are expected to own only 1.5% of the combined company after the transaction closes.

Why it matters

Monteverde & Associates is a prominent law firm that has recovered millions of dollars for shareholders through class action lawsuits. Their investigation suggests potential concerns about the fairness of the Cyclerion-Korsana merger, which could have significant implications for Cyclerion investors.

The details

Under the terms of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company after the merger with Korsana Biosciences. Monteverde & Associates is now investigating whether this deal structure is fair to Cyclerion's shareholders.

  • The proposed merger between Cyclerion Therapeutics and Korsana Biosciences is expected to close in the coming months.

The players

Monteverde & Associates PC

A national class action securities firm headquartered in New York City that has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.

Cyclerion Therapeutics, Inc.

A biopharmaceutical company that is the subject of Monteverde & Associates' investigation into the fairness of its proposed merger with Korsana Biosciences.

Korsana Biosciences, Inc.

The company that is acquiring Cyclerion Therapeutics in the proposed merger.

Juan Monteverde

The class action attorney at Monteverde & Associates PC who is leading the investigation into the Cyclerion-Korsana merger.

Got photos? Submit your photos here. ›

What they’re saying

“If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.”

— Juan Monteverde, Class Action Attorney

What’s next

Monteverde & Associates will continue its investigation into the fairness of the Cyclerion-Korsana merger, and shareholders can contact the firm for more information.

The takeaway

This investigation by a prominent class action law firm suggests potential concerns about the terms of the Cyclerion-Korsana merger, which could have significant implications for Cyclerion shareholders if the deal is deemed unfair.